Focused On-demand Library for Tryptophan--tRNA ligase, cytoplasmic

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P23381

UPID:

SYWC_HUMAN

Alternative names:

Interferon-induced protein 53; Tryptophanyl-tRNA synthetase

Alternative UPACC:

P23381; A6NGN1; A6NID3; P78535; Q502Y0; Q53XB6; Q9UDI5; Q9UDL3

Background:

Tryptophan--tRNA ligase, cytoplasmic, also known as Tryptophanyl-tRNA synthetase, plays a pivotal role in protein synthesis. It is involved in the aminoacylation of tRNA by tryptophan, facilitating the translation of mRNA into protein. This enzyme exists in multiple isoforms, each exhibiting distinct functional activities, including angiostatic activity and regulation of pathways critical for angiogenesis and endothelial cell response.

Therapeutic significance:

The protein's involvement in Neuronopathy, distal hereditary motor, 9, a disorder characterized by progressive muscle weakness, highlights its potential as a therapeutic target. Understanding the role of Tryptophan--tRNA ligase, cytoplasmic could open doors to potential therapeutic strategies for treating this neurologic disorder.